We are live on
!
Find out more
Lazard Asset Management Portfolio holdings
AUM
$60.8B
1-Year Est. Return
22.47%
This Fund
S&P 500
This Quarter
Est. Return
+11.1%
1 Year Est. Return
+22.47%
3 Year Est. Return
+62.53%
5 Year Est. Return
+77.87%
10 Year Est. Return
+305.76%
AUM
$79B
AUM Growth
+$5.52B
(+7.5%)
Cap. Flow
-$7.01B
Cap. Flow
% of AUM
-8.87%
Top 10 Holdings %
Top 10 Hldgs %
24.46%
Holding
2,559
New
284
Increased
737
Reduced
832
Closed
260
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Chubb
CB
|
+$555M |
| 2 |
American Electric Power
AEP
|
+$272M |
| 3 |
Ulta Beauty
ULTA
|
+$161M |
| 4 |
CVS Health
CVS
|
+$160M |
| 5 |
McDonald's
MCD
|
+$139M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$388M |
| 2 |
Aon
AON
|
+$211M |
| 3 |
Johnson & Johnson
JNJ
|
+$209M |
| 4 |
Norfolk Southern
NSC
|
+$162M |
| 5 |
Envista
NVST
|
+$149M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.99% |
| 2 | Financials | 14.12% |
| 3 | Healthcare | 13.38% |
| 4 | Industrials | 11.48% |
| 5 | Consumer Discretionary | 9.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1901
Biohaven
BHVN
$2.17B
| $12K | ﹤0.01% |
283
+3
| +1% | +$93 |
|
1902
LPL Financial
LPLA
$28.3B
| $12K | ﹤0.01% |
54
-230
| -81% | -$51.7K |
|
|
LNAI
1903
Lunai Bioworks
LNAI
$11M
| $12K | ﹤0.01% |
+49
| New | +$13.4K |
|
1904
Rentokil
RTO
$12.3B
| $12K | ﹤0.01% |
452
+240
| +113% | +$7.05K |
|
1905
Weis Markets
WMK
$1.89B
| $12K | ﹤0.01% |
191
-1,996
| -91% | -$127K |
|
1906
Invesco
IVZ
$14B
| $11K | ﹤0.01% |
668
+134
| +25% | +$1.93K |
|
1907
ProQR Therapeutics
PRQR
$268M
| $11K | ﹤0.01% |
5,860
-354
| -6% | -$544 |
|
1908
Scilex Holding
SCLX
$48.8M
| $11K | ﹤0.01% |
162
| – | – |
|
1909
Vanda Pharmaceuticals
VNDA
$308M
| $11K | ﹤0.01% |
2,637
-9,047
| -77% | -$36.5K |
|
1910
CBRE Group
CBRE
$42.7B
| $10K | ﹤0.01% |
110
-25,920
| -100% | -$2.02M |
|
1911
MarineMax
HZO
$776M
| $10K | ﹤0.01% |
270
+62
| +30% | +$1.96K |
|
1912
Lineage Cell Therapeutics
LCTX
$282M
| $10K | ﹤0.01% |
9,415
+578
| +7% | +$633 |
|
1913
Qorvo
QRVO
$8.41B
| $10K | ﹤0.01% |
89
+14
| +19% | +$1.35K |
|
1914
Repligen
RGEN
$9B
| $10K | ﹤0.01% |
66
-2
| -3% | -$311 |
|
|
BLUE
1915
DELISTED
bluebird bio
BLUE
| $9K | ﹤0.01% |
343
-20
| -6% | -$1.22K |
|
1916
Conagra Brands
CAG
$7.11B
| $9K | ﹤0.01% |
325
| – | – |
|
1917
iShares Core MSCI Europe ETF
IEUR
$9.08B
| $9K | ﹤0.01% |
167
-3,033
| -95% | -$155K |
|
1918
Jasper Therapeutics
JSPR
$21.5M
| $8K | ﹤0.01% |
1,150
+36
| +3% | +$242 |
|
1919
ResMed
RMD
$32.4B
| $8K | ﹤0.01% |
52
+1
| +2% | +$154 |
|
|
ADVM
1920
DELISTED
Adverum Biotechnologies
ADVM
| $7K | ﹤0.01% |
993
-56
| -5% | -$511 |
|
1921
Euroseas
ESEA
$542M
| $7K | ﹤0.01% |
+299
| New | +$6.75K |
|
1922
Fresenius Medical Care
FMS
$12.8B
| $7K | ﹤0.01% |
357
-314
| -47% | -$6.03K |
|
1923
Orion
OEC
$429M
| $7K | ﹤0.01% |
257
-1,384
| -84% | -$31.8K |
|
1924
Cartesian Therapeutics
RNAC
$257M
| $7K | ﹤0.01% |
371
-21
| -5% | -$627 |
|
|
LENZ
1925
LENZ Therapeutics
LENZ
$164M
| $7K | ﹤0.01% |
410
-24
| -6% | -$396 |
|
Similar funds
QCM
Lazard Asset Management's Q4 2023 Portfolio in Review
As of Q4 2023, Lazard Asset Management held 2,559 positions worth $79B, up 7.5% from $73.5B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Lazard Asset Management withdrew a net $7.01B in Q4 2023, closing 260 positions and reducing 832 holdings. Its most notable exit was VMware, Inc, an estimated $34.5M position sold in full.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Financials and Healthcare.
Against the trend, Lazard Asset Management opened a new position in Dentsply Sirona worth $141M.
- Lazard Asset Management's largest Q4 2023 buy was Dentsply Sirona: 3,954,444 shares worth $141M.
- Lazard Asset Management added most to Chubb in Q4 2023, an estimated $555M increase.
- Lazard Asset Management's biggest Q4 2023 reduction was Meta Platforms (Facebook), cutting an estimated $388M.
- Lazard Asset Management fully exited VMware, Inc in Q4 2023, selling an estimated $34.5M.
- Lazard Asset Management's ten largest holdings make up 24% of its $79B portfolio in Q4 2023.
- Lazard Asset Management opened 284 new positions and closed 260 in Q4 2023.
- Lazard Asset Management's portfolio value rose 7.5% quarter-over-quarter to $79B.
Based on Lazard Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.